Skip to content
value.today

Tasca Therapeutics Corp

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2021
Total raised
$48 M
1 round on record
Latest round
$48 M
Nov 2024
First round on record
Nov 2024
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tasca Therapeutics Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2024$48 MNo. 1$10 to $50 million

Tasca Therapeutics Corp: Raise no. 1, Nov 2024

Investors in this round

9 investors had bought by the notice of Dec 1, 2025: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$48 M of $70 M offered; $22 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Drew King · Executive Officer
  • Milenko Cicmil · Executive Officer, Director
  • David Fallace · Director
  • Michael Aberman · Director
  • Praveen Tipirneni · Director
  • Seth Lieblich · Director
  • Xu Wu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The proceeds are available to fund general working capital requirements; as of the date of this filing, no detailed operating budget has been adopted; and no proceeds have been or are proposed to be used for payments of finders fees or other compensation.”

Signed by Milenko Cicmil, President and CEO. Source: SEC Form D and 1 amendment, newest notice filed Dec 1, 2025. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tasca Therapeutics Corp chose not to state its revenue in its newest notice of a funding round (Dec 2025).

    SEC Form D · Dec 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2025

That is all the official record says: Tasca Therapeutics Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Tasca Therapeutics Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tasca Therapeutics Corp
NameRoleNamed in
Drew KingExecutive officerDec 2025
Milenko CicmilExecutive officerDec 2025
David FallaceDirectorDec 2025
Michael AbermanDirectorDec 2025
Milenko CicmilDirectorDec 2025
Praveen TipirneniDirectorDec 2025
Seth LieblichDirectorDec 2025
Xu WuDirectorDec 2025